Tuberculosis (TB) In-Silico Testing Arm
India carries 27% of the global tuberculosis burden and the world's highest count of multi-drug resistant (MDR/XDR-TB) cases. Traditional clinical trials face severe recruitment bottlenecks, prolonged 18–24 month regimens, and ethical barriers on physical control arms. Silicon Arm models bactericidal kill-curves and virtual control cohorts in-silico to accelerate curative regimens.
Physical Trial Deficits & Ethical Control Barriers
Despite carrying over 2.8 million active cases annually, India hosts under 3% of global clinical trials for novel chemical entities (NCEs). Traditional Phase II/III regimens require 18–24 months of physical monitoring, resulting in severe patient loss to follow-up.
Assigning MDR-TB patients with extensive resistance profiles to failing standard-of-care physical control arms creates severe ethical barriers and clinical trial attrition.
Virtual Cohort Simulation for Regimen Optimization
Silicon Arm is calibrating virtual TB cohorts matching Indian cavitary status, sputum smear grades, nutritional baselines (BMI < 18.5), and pharmacokinetic penetration into fibrotic lung lesions.
- • Synthetic Control Arms: Cuts physical control arm enrollment requirements by up to 50%, drastically de-risking IRB approval.
- • Bactericidal Kill-Curves: Simulating Early Bactericidal Activity (EBA 0–14d) and long-term sterilization kinetics across novel combination regimens.
- • 5-State Cavitary Disease Model: Predicting cavity closure timelines, sputum culture conversion, and 2-year post-treatment relapse risk.
- • MDR Resistance Mutational Dynamics: Modeling the emergence of secondary resistance under sub-inhibitory tissue concentrations.
Cavitary Lesion Pharmacokinetics
Mathematical modeling of drug permeability gradients through necrotic caseum, cellular granuloma rims, and fibrotic vascular beds to ensure lethal Cmin/MIC ratios.
Multi-Strain In-Silico Cohorts
Generating 10,000+ virtual pulmonary TB patients incorporating local Indian Beijing/Central Asian strain genotypes and baseline isoniazid/rifampicin resistance variations.
Regimen Duration Compression
Simulate whether novel 6-month short-course regimens (such as BPaL/BPaMZ) achieve non-inferior sterilizing efficacy compared to standard 18-month regimens before dosing the first patient.
Regulatory Dossier Preparation
Generating mathematically validated Bayesian survival priors ready for submission in CDSCO, ICMR, and ethics committee protocol justifications.
TB Regimen Simulation & Sputum Conversion Model
Explore simulated bactericidal trajectories and 24-month relapse risk across standard of care vs. novel in-silico simulated regimens.
In-silico simulation demonstrates rapid bactericidal kill within day 0–14 followed by sterilizing clearance of semi-dormant bacilli in necrotic cavitary rims. Achieves non-inferior clinical cure in 6 months vs. historical 18-month control regimens while eliminating 250+ physical control arm exposures.